This article is more than 5 years old. Information may no longer be current.

Allergan first quarter sales show rise

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Allergan’s pharmaceutical sales for the first quarter of 2004 increased 20.9% from the same quarter last year, and net sales totaled $472.4 million, the company announced.

Sales of Alphagan P and Alphagan (brimonidine) decreased by 10.3% to $69.3 million, while Lumigan (bimatoprost) sales increased almost 41% from the previous quarter to $53.5 million. Restasis (cyclosporine) had sales of $21.3 million in the first quarter.

Sales of Tazorac, Zorac and Avage (all tazarotene) decreased to $18 million from $19.7 million in the same period a year ago, according to a press release from Allergan.

In other news, Allergan announced that it was selected as a partner to supply triamcinolone for two National Eye Institute-sponsored trials for macular edema. The trials will investigate the efficacy and safety of a new intravitreal formula for macular edema associated with diabetic retinopathy and retinal vein occlusion.